SNU-182 Cells

The SNU-182 cell line is derived from a human hepatocellular carcinoma (HCC), which is a primary malignancy of the liver. This cell line is widely used in liver cancer research to study the molecular and cellular mechanisms underlying hepatocarcinogenesis, tumor progression, and therapeutic responses. Hepatocellular carcinoma is one of the most common and deadly forms of liver cancer, making cell lines like SNU-182 essential for advancing our understanding of the disease and developing effective treatments. SNU-182 cells exhibit an epithelial morphology and express markers typical of liver cancer, such as alpha-fetoprotein (AFP) and hepatocyte-specific antigens. They harbor genetic and epigenetic alterations that are frequently observed in HCC, including mutations in key oncogenes and tumor suppressor genes. Researchers use SNU-182 cells to explore various signaling pathways involved in liver cancer, such as the Wnt/β-catenin, PI3K/Akt, and MAPK pathways. These cells are also employed in high-throughput drug screening assays and preclinical testing of chemotherapeutic agents, targeted therapies, and combination treatments. Additionally, SNU-182 cells are utilized to study mechanisms of drug resistance and to develop strategies to overcome it. The relevance of the SNU-182 cell line in hepatocellular carcinoma research highlights its importance in advancing our knowledge of liver cancer biology and in the development of new therapeutic approaches for patients with HCC.